Medicenna to Announce Fiscal Year 2021 Financial Results and Operational Highlights on Friday, May 28, 2021

Rhea-AI Summary

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) announced a conference call on May 28, 2021, at 8:30 AM ET to share financial results for the fiscal year ended March 31, 2021, alongside operational highlights. The call can be accessed via telephone or live webcast through the company's investor relations website. Medicenna specializes in immuno-oncology, focusing on novel IL-2, IL-4, and IL-13 Superkines, including MDNA11 and MDNA55, the latter having completed a Phase 2b trial for recurrent glioblastoma and received Fast-Track and Orphan Drug designations.

Positive

• MDNA55 completed a Phase 2b trial for recurrent glioblastoma (rGBM).
• MDNA55 received Fast-Track and Orphan Drug status from the FDA and EMA.
• MDNA11 shows superior CD122 binding without CD25 affinity, enhancing cancer treatment potential.

Negative

• None.

TORONTO and HOUSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on May 28, 2021 at 8:30 AM ET to report its financial results for the fiscal year ended March 31, 2021 and operational highlights.

To access the call, please dial (877) 407-9716 from Canada or the United States or (201) 493-6779 internationally, followed by the conference ID: 13719231. To access the live webcast, please go to the investors section of Medicenna’s website at https://ir.medicenna.com/news-and-events/events-and-presentations. Following the live webcast, an archived version of the call will be available on Medicenna’s website.

About Medicenna
Medicenna is a clinical stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Superkines for the treatment of a broad range of cancers. Medicenna's long-acting IL-2 Superkine asset, MDNA11, is a next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulates cancer killing effector T cells and NK cells when compared to competing IL-2 programs. Medicenna’s early-stage program on Bifunctional SuperKine ImmunoTherapies (BiSKITs™) is designed to further enhance the ability of Superkines to treat immunologically “cold” tumors. Medicenna's lead IL4 Empowered Superkine, MDNA55, has completed a Phase 2b clinical trial for rGBM, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 subjects, including 112 adults with rGBM. MDNA55 has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

FAQ

What are the key highlights from Medicenna's conference call on May 28, 2021?

The conference call will cover Medicenna's financial results for the fiscal year ending March 31, 2021, and operational achievements.

What is MDNA55 and its significance?

MDNA55 is Medicenna's lead IL4 Empowered Superkine that has completed a Phase 2b clinical trial for recurrent glioblastoma, demonstrating its potential in treating this severe cancer.

What designations has MDNA55 received from regulatory authorities?

MDNA55 has received Fast-Track and Orphan Drug status from the FDA and EMA, which may expedite its development and approval.

How can investors access the Medicenna conference call?

Investors can access the call by dialing (877) 407-9716 from Canada or the US or via the live webcast on Medicenna’s investor relations website.

What is MDNA11 and its role in cancer treatment?

MDNA11 is a next-generation IL-2 Superkine asset designed to preferentially stimulate cancer-fighting T cells, potentially outperforming existing IL-2 programs.